BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Tedalinab

Summary

Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB2 receptor agonist. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.[1] Many related compounds are known, most of which also show high CB2 selectivity.[2]

Tedalinab
Identifiers
  • (4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide
CAS Number
  • 916591-01-0
PubChem CID
  • 24872953
ChemSpider
  • 29340966
UNII
  • 5R7X34Y6Q1
Chemical and physical data
FormulaC19H21F2N3O
Molar mass345.394 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC(C)(C)NC(=O)C1=NN(C2=C1[C@@H]3CC[C@H]2C3)C4=C(C=C(C=C4)F)F
  • InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
  • Key:NTPZXHMTJGOMCJ-WDEREUQCSA-N

See also edit

References edit

  1. ^ Glenmark’s Molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, Successfully Completes Phase I Trials. April 13, 2009.
  2. ^ Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.